501 related articles for article (PubMed ID: 14673998)
1. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Cheema GS; Roschke V; Hilbert DM; Stohl W
Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
[TBL] [Abstract][Full Text] [Related]
4. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.
Cambridge G; Isenberg DA; Edwards JC; Leandro MJ; Migone TS; Teodorescu M; Stohl W
Ann Rheum Dis; 2008 Jul; 67(7):1011-6. PubMed ID: 17962238
[TBL] [Abstract][Full Text] [Related]
5. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.
Ju S; Zhang D; Wang Y; Ni H; Kong X; Zhong R
Clin Biochem; 2006 Dec; 39(12):1131-7. PubMed ID: 17069785
[TBL] [Abstract][Full Text] [Related]
6. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients.
Hong SD; Reiff A; Yang HT; Migone TS; Ward CD; Marzan K; Shaham B; Phei WC; Garza J; Bernstein B; Stohl W
Arthritis Rheum; 2009 Nov; 60(11):3400-9. PubMed ID: 19877053
[TBL] [Abstract][Full Text] [Related]
7. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Petri M; Stohl W; Chatham W; McCune WJ; Chevrier M; Ryel J; Recta V; Zhong J; Freimuth W
Arthritis Rheum; 2008 Aug; 58(8):2453-9. PubMed ID: 18668552
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
9. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.
Carter RH; Zhao H; Liu X; Pelletier M; Chatham W; Kimberly R; Zhou T
Arthritis Rheum; 2005 Dec; 52(12):3943-54. PubMed ID: 16320342
[TBL] [Abstract][Full Text] [Related]
10. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Roschke V; Wu Y; Baker KP; Hilbert DM
Ann Rheum Dis; 2004 Sep; 63(9):1096-103. PubMed ID: 15308519
[TBL] [Abstract][Full Text] [Related]
11. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
12. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
13. Elevated expression of the Brn-3a and Brn-3b transcription factors in systemic lupus erythematosus correlates with antibodies to Brn-3 and overexpression of Hsp90.
Ripley BJ; Rahman MA; Isenberg DA; Latchman DS
Arthritis Rheum; 2005 Apr; 52(4):1171-9. PubMed ID: 15818685
[TBL] [Abstract][Full Text] [Related]
14. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
La DT; Collins CE; Yang HT; Migone TS; Stohl W
Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.
Novak AJ; Grote DM; Ziesmer SC; Kline MP; Manske MK; Slager S; Witzig TE; Shanafelt T; Call TG; Kay NE; Jelinek DF; Cerhan JR; Gross JA; Harder B; Dillon SR; Ansell SM
J Clin Oncol; 2006 Feb; 24(6):983-7. PubMed ID: 16432079
[TBL] [Abstract][Full Text] [Related]
16. [Expression and clinical significance of inducible co-stimulator on peripheral blood T lymphocyte subsets in patients with systemic lupus erythematosus].
Yang JH; Shen Q; Zhao DB; Cai Q; Han XH
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(5):318-23. PubMed ID: 15854508
[TBL] [Abstract][Full Text] [Related]
17. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.
Tan SM; Xu D; Roschke V; Perry JW; Arkfeld DG; Ehresmann GR; Migone TS; Hilbert DM; Stohl W
Arthritis Rheum; 2003 Apr; 48(4):982-92. PubMed ID: 12687540
[TBL] [Abstract][Full Text] [Related]
18. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.
Kawasaki A; Tsuchiya N; Fukazawa T; Hashimoto H; Tokunaga K
Genes Immun; 2002 Nov; 3(7):424-9. PubMed ID: 12424625
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
[TBL] [Abstract][Full Text] [Related]
20. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.
Anolik JH; Barnard J; Cappione A; Pugh-Bernard AE; Felgar RE; Looney RJ; Sanz I
Arthritis Rheum; 2004 Nov; 50(11):3580-90. PubMed ID: 15529346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
